These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7635573)

  • 21. Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy.
    Erlandsson E; Andersson K; Cavallin A; Nilsson A; Larsson-Lorek U; Niss U; Sjöberg A; Wallén-Ohman M; Antonsson P; Walse B; Forsberg G
    J Mol Biol; 2003 Nov; 333(5):893-905. PubMed ID: 14583188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective adoptive immunotherapy by T-LAK cells retargeted with bacterial superantigen-conjugated antibody to MUC1 in xenografted severe combined immunodeficient mice.
    Shinoda M; Kudo T; Suzuki M; Katayose Y; Sakurai N; Saeki H; Kodama H; Fukuhara K; Imai K; Hinoda Y; Matsuno S
    Cancer Res; 1998 Jul; 58(13):2838-43. PubMed ID: 9661899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
    Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G
    Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antagonistic effects of the staphylococcal enterotoxin a mutant, SEA(F47A/D227A), on psoriasis in the SCID-hu xenogeneic transplantation model.
    Boehncke WH; Hardt-Weinelt K; Nilsson H; Wolter M; Dohlsten M; Ochsendorf FR; Kaufmann R; Antonsson P
    J Invest Dermatol; 2001 Apr; 116(4):596-601. PubMed ID: 11286628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
    Sundstedt A; Celander M; Hedlund G
    Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxic T lymphocyte-dependent tumor growth inhibition by a vascular endothelial growth factor-superantigen conjugate.
    Sun Q; Jiang S; Han B; Sun T; Li Z; Zhao L; Gao Q; Sun J
    Biochem Biophys Res Commun; 2012 Nov; 427(4):711-7. PubMed ID: 23036194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-tumor effect and mechanism of SEA-Fab' coupled protein on gastric tumor.
    Shu X; Wang G
    J Huazhong Univ Sci Technolog Med Sci; 2005; 25(5):549-51. PubMed ID: 16463671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses.
    Litton MJ; Dohlsten M; Hansson J; Rosendahl A; Ohlsson L; Kalland T; Andersson J; Andersson U
    Am J Pathol; 1997 May; 150(5):1607-18. PubMed ID: 9137087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with tumor-reactive Fab-IL-2 and Fab-staphylococcal enterotoxin A fusion proteins leads to sustained T cell activation, and long-term survival of mice with established tumors.
    Søgaard M; Ohlsson L; Kristensson K; Rosendahl A; Sjoberg A; Forsberg G; Kalland T; Dohlsten M
    Int J Oncol; 1999 Nov; 15(5):873-82. PubMed ID: 10536168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted superantigens for immunotherapy of haematopoietic tumours.
    Tötterman TH; Gidlöf C; Ragnarsson L; Högbom E; Lindeberg M; von der Lehr N; Einarsson A; Soegaard M; Kristensson K; Kalland T; Dohlsten M
    Vox Sang; 1998; 74 Suppl 2():483-7. PubMed ID: 9704486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
    Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
    Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II.
    Lando PA; Olsson C; Kalland T; Newton D; Kotb M; Dohlsten M
    J Immunol; 1996 Oct; 157(7):2857-63. PubMed ID: 8816390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth.
    Rosendahl A; Kristensson K; Hansson J; Ohlsson L; Kalland T; Dohlsten M
    Int J Cancer; 1998 Apr; 76(2):274-83. PubMed ID: 9537591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
    Takemura S; Kudo T; Asano R; Suzuki M; Tsumoto K; Sakurai N; Katayose Y; Kodama H; Yoshida H; Ebara S; Saeki H; Imai K; Matsuno S; Kumagai I
    Cancer Immunol Immunother; 2002 Mar; 51(1):33-44. PubMed ID: 11845258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
    Forsberg G; Skartved NJ; Wallén-Ohman M; Nyhlén HC; Behm K; Hedlund G; Nederman T
    J Immunother; 2010 Jun; 33(5):492-9. PubMed ID: 20463598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intercellular adhesion molecule-1 and leukocyte function-associated antigen-3 provide costimulation for superantigen-induced T lymphocyte proliferation in the absence of a specific presenting molecule.
    Lamphear JG; Stevens KR; Rich RR
    J Immunol; 1998 Jan; 160(2):615-23. PubMed ID: 9551895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro biological activities of transmembrane superantigen staphylococcal enterotoxin A fusion protein.
    Ma W; Yu H; Wang Q; Bao J; Yan J; Jin H
    Cancer Immunol Immunother; 2004 Feb; 53(2):118-24. PubMed ID: 14574492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Solid tumor-targeted infiltrating cytotoxic T lymphocytes retained by a superantigen fusion protein.
    Sun J; Zhao L; Teng L; Lin F; Zhang H; Li Z; Gao Q
    PLoS One; 2011 Feb; 6(2):e16642. PubMed ID: 21311755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repeated treatment with S. aureus superantigens expands the survival rate of Ehrlich ascites tumor bearing mice.
    Mondal TK; Bhatta D; Biswas S; Pal P
    Immunol Invest; 2002 Feb; 31(1):13-28. PubMed ID: 11990460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.